James F. Lynch, PhD, MBA
Dr. James F. Lynch earned his Bachelor Of Science (BS) degree in Chemistry at Siena College, subsequently completing his Masters (MS) and Doctoral (PhD) degrees in Inorganic Chemistry at Seton Hall University, and a Masters in Business Administration (MBA) at Columbia University.
Dr. Lynch brings over two decades of pharmaceutical industry experience to us, ranging from scientific research and drug development, to holding executive and management/consulting positions with successful startups and Fortune 500 companies including Pfizer, Inc. and Sandoz Pharmaceutical Corporation (now, Novartis Pharmaceutical Corporation).
Prior to joining PhytoMedical, Dr. Lynch served as Vice President, Global Business Development at Savient Pharmaceuticals, a specialty pharmaceutical company. Previously, he was a founding member of Reliant Pharmaceuticals, LLC, a start-up company where he served as Executive Director of Business Development and Vice President of Commercial Operations.
As a Managing Consultant with PA Consulting Group, a UK-based global technology consulting firm, Dr. Lynch directed global projects for major pharma clients including the world’s largest pharmaceutical company, Pfizer, Inc., focusing on strategic portfolio planning, drug development harmonization, capacity/capabilities assessment and outsourcing.
Dr. Lynch spent nine years at Sandoz/Novartis where he held numerous managerial positions in various functional areas, including New Product Management and Licensing, Drug Development and Project Lead for Cardiovascular and Diabetes Drug Development.
Charles Lee, PhD
Dr. Charles Lee earned his PhD in Pharmaceutical Chemistry/Pharmacokinetics at the University of California, San Francisco, and his MS degree in Physical Chemistry at Auburn University in Auburn, Alabama.
Over the course of thirty years in pharmaceutical sciences, Dr. Charles Lee has served in numerous industry and academic positions, including his recent tenure as Professor of Pharmaceutical Sciences at the Gregory School of Pharmacy, Palm Beach Atlantic University. Previously, Dr. Lee served as Assistant Professor, University of Florida, College of Pharmacy, and as Associate Professor at the University of Houston, College of Pharmacy.
Dr. Charles Lee is an accomplished researcher with several book chapters to his credit, and publications in peer-reviewed scientific journals such as the Journal of Clinical Pharmacology, Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, and others.
Dr. Lee has served as an Ad Hoc reviewer for several National Institutes of Health study sections in the United States, and as Advisor, Bureau of Pharmaceutical Affairs, Department of Health, in Taiwan.
An expert in pharmaceutical sciences, Dr. Lee previously served as Director of Pharmacokinetics with NYSE-listed, KV Pharmaceuticals, where among other duties, he coordinated and supervised the preparation of numerous applications to the FDA, including Investigational New Drug, New Drug Application, and Abbreviated New Drug Application submissions. Dr. Charles Lee also served as the company’s liaison to the FDA in the United States, and foreign health authorities in Canada and Japan.
Subsequently, Dr. Charles Lee served as Assistant Director, Clinical Pharmacology at Wyeth Research, one of the world's largest research-driven pharmaceutical and health care products companies. Following his term at Wyeth, Dr. Charles Lee joined Fujisawa Healthcare, a division of Fujisawa Pharmaceuticals (now Astellas), founded in 1894 and ranked among Japan’s top five pharmaceutical companies.
Mark Bossie, PhD
Dr. Bossie received a B.S. degree in Biology from The College of New Jersey (formerly Trenton State), and earned his PhD in Microbiology and Molecular Biology at Rutgers University. Following his graduate studies, Dr. Mark Bossie joined the Molecular Biology Department at Princeton University, where he undertook and completed his post-doctoral research efforts.
Upon completion of his post-doctoral work, Dr. Bossie joined Bristol Myers-Squibb, developers of the world’s most widely used cancer treatment, Taxol®, a naturally-derived pharmaceutical compound.
Subsequently, Dr. Bossie accepted appointment as Senior Research Scientist at the Plant Biotechnology Department at American Cyanamid, and quickly rose to the rank of Group Leader, managing and leading research teams in various projects, including compound discovery.
Dr. Bossie was a central figure in the establishment of American Cyanamid’s most significant ventures into genomics-based discovery and initiatives into the use of plant biotechnology outside of crop protection.
Following the sale of American Cyanamid to BASF, Dr. Bossie accepted appointment as Research Director at Icon Genetics, a biotechnology company engaged in developing novel plant technologies targeted at the production of therapeutic pharmaceuticals in plant-based production systems.
Since the successful sale of Icon Genetics’ US interests, Dr. Mark A. Bossie has provided private consulting in the areas of biotechnology, and scientific and medical communications, working across a wide array of therapeutic disciplines for some of the world’s leading pharmaceutical companies.
|
